<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02830737</url>
  </required_header>
  <id_info>
    <org_study_id>SWH2015LC02</org_study_id>
    <nct_id>NCT02830737</nct_id>
  </id_info>
  <brief_title>No-touch RFA Versus Traditional RFA for Small Hepatocellular Carcinoma</brief_title>
  <official_title>Prospective Randomized Comparative Study on No-touch Radiofrequency Ablation Treatment of Small Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditional RFA treatment has been a curable therapy for small hepatocellular carcinoma&#xD;
      (diameter≤3cm). This technique ablates the tumor via radio frequency by inserting an&#xD;
      electrode needle directly into the tumor. This clearly violates no-touch technique based on&#xD;
      the principle of surgical oncology. Thus the 1-year recurrence rate of the cancer is up to&#xD;
      30% after the treatment, and the 3-year tumor-free survival rate is only 20% - 40%. No-touch&#xD;
      RFA treatment avoids the direct contact with the tumor that can cause the spread of cancer&#xD;
      cells in the liver, or the Antrim spread, Therefore it has been suggested that no-touch RFA&#xD;
      treatment reduce the recurrence rate after operation in comparison with the traditional RFA&#xD;
      treatment. This research project aims at using the prospective randomized comparative method&#xD;
      to compare the short-term and the long-term curative effects between no-touch RFA and&#xD;
      traditional RFA treatments for small hepatic carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence Rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free Survival Rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Traditional RFA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using Traditional RFA for the treatment of small hepatocellular carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-touch RFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using No-touch RFA for the treatment of small hepatocellular carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Traditional RFA</intervention_name>
    <description>Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the lesion center</description>
    <arm_group_label>Traditional RFA</arm_group_label>
    <other_name>RFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No-touch RFA</intervention_name>
    <description>Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the tumor-free zone (within 5mm along the edge of the tumor)</description>
    <arm_group_label>No-touch RFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary hepatocellular carcinoma, according to the postoperative pathological&#xD;
             examination as the standard, or the diagnostic criteria with reference to the 2012&#xD;
             American Association for the Study of Liver Diseases if the pathological evidence is&#xD;
             not available;&#xD;
&#xD;
          2. A single tumor with a diameter ≤3cm;&#xD;
&#xD;
          3. The tumor that has not invaded the portal vein, the hepatic vein, or the secondary&#xD;
             branch;&#xD;
&#xD;
          4. Liver function classified as Child A or B;&#xD;
&#xD;
          5. Liver reserve function test with ICG-R15 (indocyanine green retention at 15min) ≤30%,&#xD;
             and the important organs that can function with the tolerance of RFA or partial&#xD;
             hepatectomy;&#xD;
&#xD;
          6. No significant coagulopathy: platelet count &gt; 50,000,000,000 /L, prolonged prothrombin&#xD;
             time &lt; 5 seconds;&#xD;
&#xD;
          7. Age 18 - 70 years old;&#xD;
&#xD;
          8. No acceptance of other anti-cancer therapy before the treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Complication of severe portal hypertension: a history of upper gastrointestinal&#xD;
             bleeding, a history of severe hypersplenism, or refractory ascites;&#xD;
&#xD;
          2. Patients with extrahepatic metastasis or lymph node metastasis;&#xD;
&#xD;
          3. Patients with multiple liver tumors found from imaging exam or during the treatment;&#xD;
&#xD;
          4. Patients with pathological examinations showing the other tissue type of liver cancer&#xD;
             after the treatment;&#xD;
&#xD;
          5. Patients who expect to receive a liver transplant;&#xD;
&#xD;
          6. Patients whose preoperative imaging exam indicates the tumor close to the gallbladder,&#xD;
             hilar major blood vessels, bile ducts and surrounding vital organs, with a potential&#xD;
             of serious injury by mistake or serious complications during the treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ma Kuansheng, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Institute of hepatobiliary surgery,Southwest Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of hepatobiliary surgery,Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>Yuelong Chai</investigator_full_name>
    <investigator_title>Candidate of Doctor in Medicine</investigator_title>
  </responsible_party>
  <keyword>Small Hepatocellular Carcinoma</keyword>
  <keyword>No-touch RFA</keyword>
  <keyword>Traditional RFA</keyword>
  <keyword>Recurrence rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

